Category - News

Developments

Profound Medical’s TULSA procedure featured at AUA

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...

May 1, 2023

Markets

Dawson James ups Can-Fite to buy on valuation call

Dawson James upgraded Can-Fite BioPharma (NYSE American, TASE:CANF) to “buy” from “neutral” with a $6 price target. The stock closed at $1.74 on April 28. Analyst Jason Kolbert writes that the stock is reaching new lows...

May 1, 2023

Developments

Kiora RP treatment seen restoring visual function in blind patients

Kiora Pharmaceuticals (NASDAQ:KPRX) presented preliminary results from an ongoing clinical trial, showing that its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind...

April 28, 2023

Markets

RJ starts WELL Health at OP; PT $8.50 (Canadian)

Raymond James initiated coverage of WELL Health Technologies (TSX:WELL) with an “outperform” rating and price target of $8.50 (Canadian). The stock closed at $5.46 on April 27. WELL Health operates a hybrid care...

April 28, 2023

Developments

Avidity posts positive Phase 1/2 topline data in myotonic dystrophy 1

Avidity Biosciences (NASDAQ:RNA) reported positive topline data from the Phase 1/2 MARINA clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal...

April 28, 2023

Markets

Cantor starts Disc Medicine at OW; PT $45

Cantor Fitzgerald launched coverage of Disc Medicine (NASDAQ:IRON) with an “overweight” rating and 12-month price target of $45. The stock closed at $32.24 on April 27. Disc Medicine is a clinical-stage...

April 28, 2023

Markets

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given updated data released in the fourth...

April 27, 2023

Developments

SAB posts positive Phase 3 results in high-risk COVID-19 patients

SAB Biotherapeutics (NASDAQ:SABS) reported positive top-line results from the Phase 3 National Institutes of Health’s ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at...

April 26, 2023

Developments

Morphic posts positive cohort data in ulcerative colitis

Morphic Therapeutic (NASDAQ:MORF) reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with...

April 25, 2023

Developments

Lyra restarts Phase 3 trial in chronic rhinosinusitis

Lyra Therapeutics (NASDAQ:LYRA) resumed screening and enrollment in ENLIGHTEN II, its second Phase 3 clinical trial of LYR-210 in patients with chronic rhinosinusitis (CRS). LYR-210 is a bioresorbable nasal implant...

April 25, 2023

Category - News

Subscribe